Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | CNR1 | P21554 | 5/20 | 0.48 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4185132 | 0.99 | CNR2 (0.47) | CNR2CNR1PBKKDM4EALDH1A1 | |
| SCHEMBL6012264 | 0.89 | CNR2 (0.60) | CNR2CNR1KDM4EALDH1A1GAA | |
| SCHEMBL4200640 | 0.84 | CNR2 (0.47) | CNR2CNR1TYK2RAB9AL3MBTL1 | |
| SCHEMBL13929052 | 0.84 | CNR2 (0.47) | CNR2CNR1TYK2RAB9AL3MBTL1 | |
| SCHEMBL13929062 | 0.81 | SMYD3 (0.50) | SMYD3 | |
| SCHEMBL4187279 | 0.81 | PDE4B (0.44) | TYK2SMYD3 | |
| SCHEMBL13929064 | 0.81 | SMYD3 (0.49) | CNR2TYK2SMYD3 | |
| Hydrochloric Acid SCHEMBL4186986 | 0.81 | SMYD3 (0.49) | SMYD3 | |
| SCHEMBL8303135 | 0.81 | PDE4B (0.44) | TYK2SMYD3 | |
| Hydrochloric Acid SCHEMBL4200643 | 0.80 | SMYD3 (0.48) | CNR2TYK2SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | CNR2 571/4885CNR1 529/4885PBK 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.